You are here

Short Bites: Updates from AIDS 2020 Virtual

Interesting HIV medication and treatment highlights from the 23rd International AIDS Conference (AIDS 2020), held virtually, July 6-10, 2020.

Long-acting injectable CAB is more effective in preventing HIV than daily oral Truvada

Updated results from the HPTN 083 study found that cabotegravir (CAB) for long-acting injectable PrEP is not only just as effective, but superior, to daily oral Truvada for PrEP.

First possible case of adult with HIV to achieve long-term remission without a bone marrow transplant

Data from a pilot proof-of-concept study from the Federal University of Sao Paulo revealed that one of five individuals receiving intensified multidrug antiretroviral therapy (ART) with twice-daily nicotinamide for 48 weeks, a 34-year-old Brazilian male diagnosed with HIV in 2012, maintained long-term HIV remission without the need for a bone marrow transplant.

New insights into the potential link between DTG and neural tube defects 

Encouraging new data presented from the ongoing Tsepamo study found low levels of neural tube defects in infants born to women on dolutegravir (DTG) at the time of conception and in infants born to women who started taking dolutegravir during pregnancy. Earlier study data showed that the rate of neural tube defects with dolutegravir was not significantly higher than with efavirenz or other antiretroviral therapy.

PrEP impact on reducing new HIV infections better than expected

Interim results from the ongoing SEARCH study, a population-based study in 16 rural Kenyan and Ugandan communities, found that new HIV infections were 79% lower among people who initiated PrEP and subsequently received HIV testing than in matched controls in 2015-2017 before PrEP was generally available. Over 7,143 person-years of follow up, just 0.35% of people who had initiated PrEP were diagnosed with HIV versus 1.42% among matched controls.

Browse more by: